Supplemental Material

Use of viral load to improve survey estimates of known HIV-positive status and antiretroviral treatment coverage

Peter W. Young, Emily Zielinski-Gutierrez, Joyce Wamicwe, Irene Mukui, Andrea A. Kim, Anthony Waruru, Clement Zeh, Mirjam E. Kretzschmar, Kevin M. De Cock

 Table S1. Self-reported HIV status and antiretroviral treatment (ART) use, KAIS 2012

	Unaware	Aware, not on ART	Aware, on ART		
Characteristic	n (%)	n (%)	n (%)	N	
Gender					
Male	120 (62.0)	22 (11.0)	51 (27.0)	193	
Female	223 (47.8)	78 (17.5)	154 (34.7)	455	
Age					
15-24 yrs	59 (82.0)	10 (10.9)	6 (7.1)	75	
25-34 yrs	121 (58.9)	40 (20.0)	48 (21.1)	209	
35-49 yrs	120 (44.1)	40 (14.8)	104 (41.1)	264	
50-64 yrs	43 (43.1)	10 (8.9)	47 (48.0)	100	
Marital status					
Single/never married	67 (73.5)	10 (9.8)	16 (16.7)	93	
Married / cohabitating	210 (54.2)	57 (14.4)	118 (31.4)	385	
Divorced / sep / widowed	66 (38.9)	33 (19.7)	71 (41.5)	170	
Highest educational attainment					
None	49 (53.9)	12 (12.9)	28 (33.2)	89	
Primary	192 (55.8)	60 (17.5)	94 (26.7)	346	
Secondary	18 (57.4)	3 (11.2)	10 (31.4)	31	
Higher	83 (47.4)	25 (11.9)	73 (40.8)	181	
Employment					
Unemployed	124 (49.1)	33 (14.7)	82 (36.2)	239	
Employed	218 (55.1)	67 (15.3)	123 (29.6)	408	
Mobility					
Not away for >1 month in last year	196 (54.6)	52 (14.2)	112 (31.2)	360	
Away >1 month in last year	131 (51.4)	45 (16.6)	87 (32.1)	263	
ARV biomarker					
Present	55 (25.2)	12 (4.5)	168 (70.4)	235	
Absent	233 (72.3)	73 (22.3)	18 (5.4)	324	
UVL biomarker					
Present	65 (28.7)	25 (9.9)	145 (61.3)	235	
Absent	253 (66.5)	74 (19.2)	55 (14.3)	382	
Total	343 (53.1)	100 (15.1)	205 (31.8)	648	


<u>Note</u>: ARV biomarker: test for presence of antiretrovirals in blood, UVL biomarker: present if respondent had undetectable viral load (<550 copies/mL) in blood. Missing values: one respondent was missing education and employment status, respectively, while 89 respondents were missing the ARV biomarker and 31 were missing viral load measure. Percentages are weighted to account for survey design.

Table S2. Comparison of antiretroviral (ARV) detection and undetectable viral load (UVL) by self-reported HIV status, KAIS 2012

UVL biomarker **ARV** Present Absent Missing Total Status biomarker present absent **Unaware of HIV-positive status** missing total present Aware of HIV-positive status, not absent on ART missing total present Aware of HIV-positive status, on absent ART missing total present Self-reported adherent last absent 30 days missing total present Self-reported non-adherent absent last 30 days missing total Ν

<u>Note</u>: ARV biomarker is present if ARVs detected in blood, UVL biomarker present if viral load undetectable (<550 copies/mL). Self-reported adherence is based on response to question among those who self-reported aware of HIV-positive status and on ART: 'In the last 30 days, have you missed taking any of your ARV pills?' One respondent who reported 'don't know' to this question was excluded from the self-reported adherence analysis.

Figure S1. Absolute and relative changes in ART coverage and HIV cascade indicators due to adjustment, by covariates, KAIS 2012



<u>Note</u>: relative differences are shown on log (2) scale, All differences are shown versus self-report. self-report only, self-report or ARV: either self-reported known-positive/on ART or ARVs detected, self-report or UVL: either self-reported known-positive/on ART or viral load was undetectable.

Table S3. Sensitivity analysis of self-reported and adjusted estimates of HIV care cascade restricted to participants with ARV and UVL biomarkers present, KAIS 2012

Characteristic		Sel	f-report		Self-re	port or A	RV	Self-re	eport or U	VL	Self-repo	ort, ARV or	UVL
Variable	level	n	%	se	n	%	se	n	%	se	n	%	se
Awareness of	HIV infection (1st 9	90)											
Gender	Male	62	37.1	4.5	81	50.0	5.3	82	50.3	5.3	86	52.4	5.4
	Female	207	55.8	3.0	243	65.5	2.7	241	64.9	2.7	252	67.9	2.7
Age group	15-24 yrs	15	21.7	6.0	23	39.2	7.9	25	44.8	8.4	26	46.2	8.3
	25-34 yrs	76	42.0	4.6	90	50.3	4.7	86	46.9	4.7	95	53.0	4.7
	35–49 yrs	126	56.5	4.0	149	67.7	3.6	148	67.5	3.6	152	68.5	3.6
	50–64 yrs	52	58.5	5.8	62	69.4	5.5	64	71.2	5.3	65	72.0	5.3
Total		269	48.5	3.0	324	59.4	3.0	323	59.2	3.1	338	61.8	3.1
ART coverage	among previously-	diagnosed (2	2nd 90)										
Gender	Male	44	71.8	6.4	66	81.8	5.0	68	82.9	4.6	73	84.3	4.4
	Female	141	68.0	3.4	185	76.0	3.0	191	79.3	2.9	204	80.8	2.8
Age group	15-24 yrs	6	41.8	10.8	14	67.8	10.0	18	77.5	7.4	19	78.2	7.2
	25-34 yrs	42	51.8	6.4	58	61.8	5.7	55	60.5	5.9	65	65.5	5.6
	35–49 yrs	94	75.4	4.5	123	82.8	3.7	127	86.1	3.0	132	86.9	2.9
	50–64 yrs	43	84.9	5.4	56	92.4	3.7	59	93.6	2.9	61	95.0	2.6
Total		185	69.2	3.5	251	77.9	3.0	259	80.5	2.7	277	81.9	2.6
Viral suppressi	ion among those o	n ART (3rd 9	0)										
Gender	Male	32	75.5	6.4	49	78.0	5.1	56	84.3	4.4	56	79.6	4.8
	Female	108	76.5	4.0	139	75.3	3.6	158	82.7	3.0	158	77.6	3.3
Age group	15-24 yrs	2	34.6	19.8	9	72.4	11.3	14	82.9	7.8	14	79.7	8.4
	25-34 yrs	27	58.4	8.6	33	50.3	7.5	40	68.1	7.2	40	55.5	7.0
	35–49 yrs	77	83.3	4.2	101	84.8	3.6	110	87.8	3.1	110	85.7	3.3
	50–64 yrs	34	80.6	6.4	45	82.2	5.4	50	85.6	5.0	50	83.3	5.1
Total		140	76.2	3.4	188	76.2	3.0	214	83.2	2.5	214	78.2	2.7

<u>Note</u>: self-reported: self-report only, self-report or ARV: either self-reported known-positive/on ART or ARVs detected, self-report or UVL: either self-reported known-positive/on ART or viral load was undetectable, n: unweighted numerator, se: standard error, viral suppression defined as <1000 copies/mL. Percentages and standard errors are weighted and adjusted to account for the survey design.